BR112022009672A2 - Tratamento de cânceres com conjugados anticorpo-fármaco (adc) que se ligam a proteínas 191p4d12 - Google Patents
Tratamento de cânceres com conjugados anticorpo-fármaco (adc) que se ligam a proteínas 191p4d12Info
- Publication number
- BR112022009672A2 BR112022009672A2 BR112022009672A BR112022009672A BR112022009672A2 BR 112022009672 A2 BR112022009672 A2 BR 112022009672A2 BR 112022009672 A BR112022009672 A BR 112022009672A BR 112022009672 A BR112022009672 A BR 112022009672A BR 112022009672 A2 BR112022009672 A2 BR 112022009672A2
- Authority
- BR
- Brazil
- Prior art keywords
- adc
- bind
- antibody
- proteins
- drug conjugates
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 6
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
TRATAMENTO DE CÂNCERES COM CONJUGADOS ANTICORPO-FÁRMACO (ADC) QUE SE LIGAM A PROTEÍNAS 191P4D12. A presente invenção refere-se a métodos para o tratamento de cânceres com conjugados anticorpo-fármaco (ADC) que ligam a proteínas 191P4D12.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962940209P | 2019-11-25 | 2019-11-25 | |
US201962944890P | 2019-12-06 | 2019-12-06 | |
PCT/US2020/061923 WO2021108353A1 (en) | 2019-11-25 | 2020-11-24 | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009672A2 true BR112022009672A2 (pt) | 2022-08-16 |
Family
ID=76130717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009672A BR112022009672A2 (pt) | 2019-11-25 | 2020-11-24 | Tratamento de cânceres com conjugados anticorpo-fármaco (adc) que se ligam a proteínas 191p4d12 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230025600A1 (pt) |
EP (1) | EP4065173A4 (pt) |
JP (1) | JP2023502517A (pt) |
KR (1) | KR20220106779A (pt) |
CN (1) | CN115397473A (pt) |
AU (1) | AU2020391623A1 (pt) |
BR (1) | BR112022009672A2 (pt) |
CA (1) | CA3162282A1 (pt) |
IL (1) | IL293209A (pt) |
MX (1) | MX2022006289A (pt) |
TW (1) | TW202133885A (pt) |
WO (1) | WO2021108353A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024501121A (ja) * | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA110495C2 (en) * | 2010-09-29 | 2016-01-12 | Agensys Inc | Antibody drug conjugates (adc's) that bind to 191p4d12 protein |
JP6117921B2 (ja) * | 2012-07-12 | 2017-04-19 | ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド | 細胞毒性剤と細胞結合受容体との共役体 |
US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US10669338B2 (en) * | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
-
2020
- 2020-11-24 MX MX2022006289A patent/MX2022006289A/es unknown
- 2020-11-24 TW TW109141151A patent/TW202133885A/zh unknown
- 2020-11-24 CN CN202080094301.9A patent/CN115397473A/zh active Pending
- 2020-11-24 BR BR112022009672A patent/BR112022009672A2/pt unknown
- 2020-11-24 EP EP20893544.5A patent/EP4065173A4/en active Pending
- 2020-11-24 KR KR1020227020967A patent/KR20220106779A/ko unknown
- 2020-11-24 CA CA3162282A patent/CA3162282A1/en active Pending
- 2020-11-24 WO PCT/US2020/061923 patent/WO2021108353A1/en active Application Filing
- 2020-11-24 AU AU2020391623A patent/AU2020391623A1/en active Pending
- 2020-11-24 IL IL293209A patent/IL293209A/en unknown
- 2020-11-24 US US17/779,068 patent/US20230025600A1/en active Pending
- 2020-11-24 JP JP2022530172A patent/JP2023502517A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230025600A1 (en) | 2023-01-26 |
WO2021108353A1 (en) | 2021-06-03 |
MX2022006289A (es) | 2022-06-29 |
CN115397473A (zh) | 2022-11-25 |
IL293209A (en) | 2022-07-01 |
TW202133885A (zh) | 2021-09-16 |
JP2023502517A (ja) | 2023-01-24 |
CA3162282A1 (en) | 2021-06-03 |
KR20220106779A (ko) | 2022-07-29 |
EP4065173A1 (en) | 2022-10-05 |
EP4065173A4 (en) | 2024-03-27 |
AU2020391623A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
BR112021024236A2 (pt) | Proteínas multiespecíficas | |
BR112019000071A2 (pt) | conjugados adjuvantes de anticorpo | |
BR112017027990A2 (pt) | modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38 | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
PE20160753A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
MX371092B (es) | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. | |
CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
BR112022000337A2 (pt) | Conjugados de peptídeos de citotoxinas como terapêuticos | |
CY1121821T1 (el) | Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων | |
MX2021009138A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco. | |
CY1123525T1 (el) | Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων | |
ECSP23025680A (es) | Moléculas de unión a b7-h4 terapéuticas | |
BR112022009672A2 (pt) | Tratamento de cânceres com conjugados anticorpo-fármaco (adc) que se ligam a proteínas 191p4d12 | |
BR112022008756A2 (pt) | Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso | |
EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
BR112022002391A2 (pt) | Tratamento de câncer com conjugados anticorpo-fármaco (adc) que se ligam às proteínas 191p4d12 | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário |